AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 32 min read$ALKS

Hopkinson Craig C. sold $437K of ALKS

Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares of Alkermes plc. (ALKS) at $48.58 ($0.44M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hopkinson Craig C.
Published Aug 3, 2026, 11:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 11:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
medium confidence
Mentioned
$ALKS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The newest fact is the specific sale details: 9,000 shares sold at $48.5800 for $437,220, with holdings after sale of 69,389 shares, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure usually limits actionable fundamental implications.

03

What to watch

Insider sales under 10b5-1 can still attract short-term attention, but traders should compare with prior insider activity and the broader news flow before inferring fundamentals.

Relevance 3/10Novelty 3/10Timing: filed on 2026-08-03, transaction dated 2026-08-03

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Alkermes plc.

Company-level read

Ticker impact

$ALKSNeutralMedium confidence
Context

Alkermes Form 4 shows EVP R&D and Chief Medical Officer Craig Hopkinson sold 9,000 shares at $48.58 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and usually muted for 10b5-1 sales.

Evidence & confidence

The filing discloses the transaction size and price, but it is explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretability as new negative information.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could reflect diversification or liquidity needs rather than a view on Alkermes prospects, especially since it is under a 10b5-1 plan.

Key entities

  • issuer
    Alkermes plc

    Subject of the Form 4 insider transaction disclosure (ALKS).

  • insider
    Craig C. Hopkinson

    EVP R&D and Chief Medical Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 30
$ALKSMed

Alkermes plc Q2 2026 Earnings Call Summary

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.

yahoo.com6 min
JUL 28
$ALKSMedAI 8/10

Alkermes plc. (ALKS): Results of Operations and Financial Condition

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income

SEC EDGAR 8-K6 min
JUL 25
$ALKSMed

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.

sleepreviewmag.com5 min
JUL 23
$ALKSMed

First MS Mobility Drug Gets Green Light From NHS England

NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.

medscape.com4 min